Tricuspid atresia natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
 
(10 intermediate revisions by the same user not shown)
Line 5: Line 5:




==Overview==
Early clinical features in infants include [[ cyanosis]] of [[lips]] and [[tongue]], [[difficulty in breathing]], [[tiring easily during feeding]]. The severity of [[cyanosis]] in [[ infants]] with [[ pulmonary stenosis]] is dependent on the amount of [[ pulmonary blood flow ]]passing through [[ patent ductus arteriosus]].  After physiologic closure of [[ patent ductus arteriosus]] (PDA), the [[ cyanosis]] will be aggravated. In patients with normal [[ pulmonary blood flow]], complications of [[ heart failure]] may occur. Prognosis is generally poor without [[surgery ]] and 90% of patients will die before 10 years old.
== Natural History, Complications and Prognosis ==
== Natural History, Complications and Prognosis ==


* Early clinical features in infants include [[ cyanosis]] of [[lips]] and [[tongue]], [[difficulty in breathing]], [[tiring easily during feeding]].
* Early clinical features in infants include [[ cyanosis]] of [[lips]] and [[tongue]], [[difficulty in breathing]], [[tiring easily during feeding]].
* The severity of [[cyanosis]] in[[ infants]] with [[ pulmonary stenosis]] is dependent on the amount of[[ pulmonary blood flow ]]passing through[[ patent ductus arteriosus]].  
* The severity of [[cyanosis]] in [[ infants]] with [[ pulmonary stenosis]] is dependent on the amount of [[ pulmonary blood flow ]]passing through [[ patent ductus arteriosus]].  
* After physiologic closure of [[ patent ductus arteriosus]] (PDA), the[[ cyanosis]] will be aggravated.
* After physiologic closure of [[ patent ductus arteriosus]] (PDA), the [[ cyanosis]] will be aggravated.
* In patients with normal [[ pulmonary blood flow]], complications of[[ heart failure]] may occur.
* In patients with normal [[ pulmonary blood flow]], complications of [[ heart failure]] may occur.
* Prognosis is generally poor without [[surgery ]]and 90% of patients will die before 10 years old.  
* Prognosis is generally poor without [[surgery ]] and 90% of patients will die before 10 years old.  
* The 15-year survival of patients with [[Fontan procedure]] is approximately %92 according to Merry et al.
* The 15-year survival of patients with [[Fontan procedure]] is approximately %92.<ref name="MeryDe León2019">{{cite journal|last1=Mery|first1=Carlos M.|last2=De León|first2=Luis E.|last3=Trujillo-Diaz|first3=Daniel|last4=Ocampo|first4=Elena C.|last5=Dickerson|first5=Heather A.|last6=Zhu|first6=Huirong|last7=Adachi|first7=Iki|last8=Heinle|first8=Jeffrey S.|last9=Fraser|first9=Charles D.|last10=Ermis|first10=Peter R.|title=Contemporary Outcomes of the Fontan Operation: A Large Single-Institution Cohort|journal=The Annals of Thoracic Surgery|volume=108|issue=5|year=2019|pages=1439–1446|issn=00034975|doi=10.1016/j.athoracsur.2019.05.039}}</ref>
* Complications of [[Fontan procedure]] include:
* Complications of [[Fontan procedure]] include:<ref name="FredenburgJohnson2011">{{cite journal|last1=Fredenburg|first1=Tyler B.|last2=Johnson|first2=Tiffanie R.|last3=Cohen|first3=Mervyn D.|title=The Fontan Procedure: Anatomy, Complications, and Manifestations of Failure|journal=RadioGraphics|volume=31|issue=2|year=2011|pages=453–463|issn=0271-5333|doi=10.1148/rg.312105027}}</ref>
 
**[[Exercise intolerance]] due to [[ventricular failure]]
  *[[Exercise intolerance]] due to [[ventricular failure]]
**[[Pericardial effusion]] and[[ pleural effusion]], [[chylothorax]] and [[protein-losing enteropathy]] due to [[lymphatic dysfunction]]
  *[[Pericardial effusion]] and[[ pleural effusion]], [[chylothorax]] and [[protein-losing enteropathy]] due to [[lymphatic dysfunction]]
**[[Pulmonary embolism]], blood clot formation in shunt
  *[[Pulmonary embolism]], blood clot formation in shunt
**[[Liver failure]] and portal hypertension as a result of increased pressure in the shunt
  *[[Liver failure]] and portal hypertension as a result of increased pressure in the shunt
**[[leakage]] of the[[ anastomosis]]
  *[[leakage]] of the[[ anastomosis]]
**[[Pulmonary hypertension]]
  *[[Pulmonary hypertension]]
**[[Right atrium]] dilation
  *[[Right atrium]] dilation
**[[Arrhythmia]]
  *[[Arrhythmia]]
 
==Natural History, Complications, and Prognosis==
 
===Natural History===
 
===Complications===
* Irregular, fast [[heart rhythm]]s ([[arrhythmias]])
* Chronic [[diarrhea]] (from a disease called [[protein losing enteropathy]])
* [[Heart failure]]
* Fluid in the abdomen ([[ascites]]) and in the lungs ([[pleural effusion]])
* Blockage of the artificial [[shunt]]
* [[Stroke]]s and other [[neurological]] complications
* [[Sudden death]]
 
===Prognosis===
*The prognosis is poor in untreated patients.<ref name="pmid11096554">{{cite journal| author=Rao PS| title=Tricuspid Atresia. | journal=Curr Treat Options Cardiovasc Med | year= 2000 | volume= 2 | issue= 6 | pages= 507-520 | pmid=11096554 | doi=10.1007/s11936-000-0046-6 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11096554  }} </ref>


==References==
==References==

Latest revision as of 16:15, 8 November 2020

Tricuspid atresia Microchapters

Home

Patient Information

Overview

Pathophysiology

Causes

Differentiating Tricuspid Atresia from other Disorders

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography

Cardiac Catheterization

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Special Scenarios

Pregnancy

Case Studies

Case #1

Tricuspid atresia natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tricuspid atresia natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tricuspid atresia natural history, complications and prognosis

CDC on Tricuspid atresia natural history, complications and prognosis

Tricuspid atresia natural history, complications and prognosis in the news

Blogs on Tricuspid atresia natural history, complications and prognosis

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Tricuspid atresia natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor-In-Chief:Sara Zand, M.D.[2] Keri Shafer, M.D. [3] Priyamvada Singh, MBBS [4] Assistant Editor-In-Chief: Kristin Feeney, B.S. [5]



Overview

Early clinical features in infants include cyanosis of lips and tongue, difficulty in breathing, tiring easily during feeding. The severity of cyanosis in infants with pulmonary stenosis is dependent on the amount of pulmonary blood flow passing through patent ductus arteriosus. After physiologic closure of patent ductus arteriosus (PDA), the cyanosis will be aggravated. In patients with normal pulmonary blood flow, complications of heart failure may occur. Prognosis is generally poor without surgery and 90% of patients will die before 10 years old.

Natural History, Complications and Prognosis

References

  1. Mery, Carlos M.; De León, Luis E.; Trujillo-Diaz, Daniel; Ocampo, Elena C.; Dickerson, Heather A.; Zhu, Huirong; Adachi, Iki; Heinle, Jeffrey S.; Fraser, Charles D.; Ermis, Peter R. (2019). "Contemporary Outcomes of the Fontan Operation: A Large Single-Institution Cohort". The Annals of Thoracic Surgery. 108 (5): 1439–1446. doi:10.1016/j.athoracsur.2019.05.039. ISSN 0003-4975.
  2. Fredenburg, Tyler B.; Johnson, Tiffanie R.; Cohen, Mervyn D. (2011). "The Fontan Procedure: Anatomy, Complications, and Manifestations of Failure". RadioGraphics. 31 (2): 453–463. doi:10.1148/rg.312105027. ISSN 0271-5333.

Template:WH Template:WS